Free Trial
NASDAQ:PTCT

PTC Therapeutics (PTCT) Stock Price, News & Analysis

PTC Therapeutics logo
$48.82 -0.07 (-0.14%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$48.25 -0.57 (-1.17%)
As of 05/30/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PTC Therapeutics Stock (NASDAQ:PTCT)

Key Stats

Today's Range
$48.02
$49.09
50-Day Range
$36.19
$55.31
52-Week Range
$28.72
$58.38
Volume
790,857 shs
Average Volume
860,058 shs
Market Capitalization
$3.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.75
Consensus Rating
Moderate Buy

Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTC Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

PTCT MarketRank™: 

PTC Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 207th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    PTC Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about PTC Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for PTC Therapeutics are expected to decrease in the coming year, from ($4.52) to ($4.69) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PTC Therapeutics is -8.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PTC Therapeutics is -8.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about PTC Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.09% of the float of PTC Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    PTC Therapeutics has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in PTC Therapeutics has recently increased by 3.19%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    PTC Therapeutics does not currently pay a dividend.

  • Dividend Growth

    PTC Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.09% of the float of PTC Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    PTC Therapeutics has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in PTC Therapeutics has recently increased by 3.19%, indicating that investor sentiment is decreasing.
  • News Sentiment

    PTC Therapeutics has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for PTC Therapeutics this week, compared to 8 articles on an average week.
  • Search Interest

    Only 1 people have searched for PTCT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,469,137.00 in company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of PTC Therapeutics is held by insiders.

  • Read more about PTC Therapeutics' insider trading history.
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Stock News Headlines

"Elon’s #1 AI Stock” SET TO SOAR
Because Elon Musk's AI promises to be 100x more powerful. After all, ChatGPT just works online... While Elon's AI works in the real world.
See More Headlines

PTCT Stock Analysis - Frequently Asked Questions

PTC Therapeutics' stock was trading at $45.14 at the beginning of 2025. Since then, PTCT shares have increased by 8.2% and is now trading at $48.82.
View the best growth stocks for 2025 here
.

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its earnings results on Tuesday, May, 6th. The biopharmaceutical company reported $10.04 earnings per share for the quarter, beating analysts' consensus estimates of $0.85 by $9.19. The business's quarterly revenue was down 9.6% compared to the same quarter last year.
Read the conference call transcript
.

PTC Therapeutics' top institutional shareholders include Vanguard Group Inc. (10.86%), Armistice Capital LLC (6.86%), Wellington Management Group LLP (6.84%) and Driehaus Capital Management LLC (1.91%). Insiders that own company stock include Matthew B Klein, Stuart Walter Peltz, Michael Schmertzler, Mark Elliott Boulding, Neil Gregory Almstead, Eric Pauwels, Lee Scott Golden, Pierre Gravier, Christine Marie Utter, Emily Luisa Hill, Allan Steven Jacobson, Jerome B Zeldis, David P Southwell, Alethia Young, Stephanie Okey and Emma Reeve.
View institutional ownership trends
.

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

Last Earnings
5/06/2025
Today
5/31/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PTCT
Employees
1,410
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$63.75
High Stock Price Target
$112.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+30.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
14 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$626.60 million
Pretax Margin
-47.24%

Debt

Sales & Book Value

Annual Sales
$1.77 billion
Cash Flow
$2.35 per share
Price / Cash Flow
20.80
Book Value
($10.85) per share
Price / Book
-4.50

Miscellaneous

Free Float
72,883,000
Market Cap
$3.87 billion
Optionable
Optionable
Beta
0.52

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:PTCT) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners